BRIEF published on 03/17/2026 at 07:08, 6 days 1 hour ago Sartorius Stedim Biotech refines its strategy and aims for ambitious growth EBITDA Sartorius Stedim Biotech Product Portfolio Growth Objectives Biopharmaceutical Strategy
BRIEF published on 03/17/2026 at 07:08, 6 days 1 hour ago Sartorius Stedim Biotech Sets New Growth Targets with Biopharma Focus Advanced Therapies Market Expansion Growth Targets Biopharma Strategy Bioprocessing Technologies
PRESS RELEASE published on 03/17/2026 at 07:03, 6 days 1 hour ago Sartorius Stedim Biotech sharpens strategy with biopharma focus and sets new mid-term growth targets Sartorius Stedim Biotech sharpens focus on biopharma with new growth targets and strategic initiatives to drive above-market growth and margin expansion Sartorius Stedim Biotech Strategic Initiatives Growth Targets Biopharma Above-market Growth
BRIEF published on 03/02/2026 at 16:30, 20 days 16 hours ago Sartorius Stedim Biotech: Statement on Share Capital Share Capital Voting Rights Actions Sartorius Stedim Biotech AMF Regulations
BRIEF published on 03/02/2026 at 16:30, 20 days 16 hours ago Sartorius Stedim Biotech: Share Capital and Voting Rights Update Share Capital Voting Rights French Commercial Code Sartorius Stedim Biotech EQS News Service
PRESS RELEASE published on 03/02/2026 at 16:25, 20 days 16 hours ago Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Sartorius Stedim Biotech SA declares number of shares and voting rights in issued capital as of February 28, 2026 Voting Rights Capital Déclaration Shares Sartorius Stedim Biotech
PRESS RELEASE published on 02/16/2026 at 09:13, 1 month 6 days ago Sartorius Stedim Biotech releases Universal Registration Document 2025 Sartorius Stedim Biotech releases Universal Registration Document 2025, providing insights into its financial performance and strategic outlook for the future Financial Report Sartorius Stedim Biotech Annual Results Universal Registration Document Biopharma Industry
BRIEF published on 02/16/2026 at 09:13, 1 month 6 days ago Sartorius Stedim Biotech publishes its 2025 Universal Registration Document Consolidated Financial Statements Sartorius Stedim Biotech Universal Registration Document Fiscal Year 2025 2026 Objectives
BRIEF published on 02/16/2026 at 09:13, 1 month 6 days ago Sartorius Stedim Biotech Releases 2025 Universal Registration Document Global Operations Sartorius Stedim Biotech Universal Registration Document Biopharmaceutical Solutions 2025 Financials
PRESS RELEASE published on 02/16/2026 at 09:09, 1 month 6 days ago Sartorius Stedim Biotech SA: Information on Document Availability Sartorius Stedim Biotech releases Universal Registration Document 2025 with business development and financial statements. Leading biopharmaceutical partner based in Aubagne, France Financial Statements Business Development Sartorius Stedim Biotech Biopharmaceutical Industry Universal Registration Document
Published on 03/23/2026 at 08:00, 48 minutes ago ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 6 hours 48 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/23/2026 at 08:30, 17 minutes ago Cyberclick and HubSpot Bring Together London Business Leaders to Explore the Next Phase of AI-driven CRM
Published on 03/23/2026 at 08:26, 21 minutes ago Staking Rush in Ontario: Storm Exploration Secures the Prime Plots in the New Gold Belt
Published on 03/23/2026 at 08:20, 27 minutes ago Eurobattery Minerals becomes debt-free as the final convertible bonds are fully converted into shares
Published on 03/23/2026 at 08:00, 47 minutes ago Zentra Group plc: Unaudited interim report for the six months ended 31 December 2025
Published on 03/20/2026 at 19:00, 2 days 13 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 2 days 14 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 16:57, 2 days 15 hours ago Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 3 days 14 hours ago Filing of the 2025 Universal Registration Document
